The agreement enables Reliance Life Sciences to springboard into the US market using Medicure's commercial reach.
Medicure said it has entered an agreement with Reliance Life Sciences (RLS) to market an unnamed cardiovascular biosimilar. Medicure, a Canadian company based in Winnipeg, Alberta, referred to the biosimilar candidate only as “the product.”
As yet, RLS, based in Navi Mumbai, India, has no FDA biosimilar approvals for the US market.
RLS is a diverse pharmaceuticals company with a focus on biotherapeutics, including biosimilars, regenerative medicine, pharmaceuticals, clinical research services, and molecular medicine.
Building Up Medicure's Cardiovascular Portfolio
The agreement gives Medicure exclusive rights to market the agent in the United States, Canada, and the European Union.
"We are very pleased with the agreement we have reached with RLS. The product fits well with Medicure's mission of being a significant cardiovascular company focused on the US market," Albert Friesen, CEO of Medicure, said in a statement.
According to a 2018 analysis by IQVIA, RLS had 14 biosimilars in its pipeline, making it one of the leading biosimilar developers at the time. The Medicure statement described RLS as a company with $86 billion in annual revenues.
Medicure specializes in the development and commercialization of cardiovascular therapies. Two of the products in its portfolio are tirofiban hydrochloride (Aggrastat), an anticoagulant, and pitavastatin (Zypitamag), a cholesterol-lowering statin. Both of these products are marketed in the United States.
No further details of the biosimilar agreement or marketing plan were provided.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.